Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk c19hcq.org Martin-Vicente et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 92 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.41) Martin-Vicente et al., medRxiv, doi:10.1101/2021.03.08.21253121 Favors HCQ Favors control
Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients
Martin-Vicente et al., medRxiv, doi:10.1101/2021.03.08.21253121 (Preprint)
Martin-Vicente et al., Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in.., medRxiv, doi:10.1101/2021.03.08.21253121 (Preprint)
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 92 ICU patients with almost all treated with HCQ and only one non-HCQ treated patient that died, showing unadjusted non-statistically significant lower mortality with treatment. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; treatment or control group size extremely small.
risk of death, 59.3% lower, RR 0.41, p = 0.41, treatment 37 of 91 (40.7%), control 1 of 1 (100.0%), NNT 1.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Martin-Vicente et al., 8 Mar 2021, retrospective, Spain, preprint, 38 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21253121; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients María Martin-Vicente 1*, Raquel Almansa 2,3,4*, Isidoro Martínez 1*, Ana P. Tedim2,3, Elena Bustamante 2,5, Luis Tamayo2,6, César Aldecoa 2,7,8, José Manuel Gómez9, Gloria Renedo5, Jose Ángel Berezo6, Jamil Antonio Cedeño9, Nuria Mamolar5, Pablo García Olivares9, Rubén Herrán2,6, Ramón Cicuendez5, Pedro Enríquez2,6, Alicia Ortega2,3, Noelia Jorge2,3,4, Amanda de la Fuente2,3, Juan Bustamante-Munguira10, María José Muñoz-Gómez1, Milagros González-Rivera11, Carolina Puertas11, Vicente Más 12, Mónica Vázquez12 , Felipe PérezGarcía13, Jesús Rico-Feijoo 2,8, Silvia Martín2,8, Anna Motos4,14, Laia Fernandez-Barat 4,14, Jose María Eiros15, Marta Dominguez-Gil15, Ricard Ferrer4,16, Ferrán Barbé 4,17, David J Kelvin4,18,19†, Jesús F Bermejo-Martin 2,3,4†, Salvador Resino 1†, Antoni Torres4,14†. *These authors contributed equally † These authors contributed equally 1. Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. 2. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain 3. Hospital Universitario Río Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 4. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21253121; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 5. Intensive Care Unit, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud. Av. Ramón y Cajal, 3, 47003 Valladolid, Spain 6. Intensive Care Unit, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 7. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain. 8. Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud, Calle Dulzaina, 2, 47012 Valladolid, Spain. 9. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain. 10. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid. Gerencia Regional de Salud, Av. Ramón y Cajal, 3, 47003 Valladolid, Spain 11. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain. 12. Unidad de Biología Viral, Centro Nacional de Microbiología,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit